Press

CAMH receives first Canadian federal (CIHR) grant to study psilocybin

Jul 27 • 4 min read

The Centre for Addiction and Mental Health (CAMH) has just been awarded Canada’s first federal grant to study psilocybin—the chemical component of “magic mushrooms”—with regard to its effect on treatment-resistant depression. More specifically, researchers will explore whether experiencing psilocybin’s psychedelic effects are required for it to have antidepressant effects. “There has been a growing interest and body…

COMPASS Pathways to announce second quarter 2022 financial results on August 4, 2022

Jul 26 • 2 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2022, and provide an update on recent business developments on 4 August 2022. The management team will host a conference call at…

Silo Wellness Organizes Jamaican Psilocybin Retreat Team and Advocates to Speak to Lane County Commissioners Regarding BM109 Optout Vote; Lane County Declines to Refer a Psilocybin Ban to Voters

Jul 26 • 4 min read

Silo Wellness Inc. (CSE: SILO | OTCQB: SILFD | FSE: 3K70), a leading global psychedelics company, is pleased to announce that the Silo Wellness team coordinated the presentations of eight speakers in support of psilocybin use under Ballot Measure 109 in Lane County, Oregon, (Oregon’s largest county by population outside the Portland metro area) at…

FTO Files Requests for Reconsideration of U.S. Patent Trial and Appeal Board’s Decisions Concerning Petitions for Post Grant Review of Compass Patents

Jul 25 • 3 min read

The non-profit Freedom to Operate (FTO) announced today that it has filed requests for reconsideration [PRG2022-00012 and PRG2022-00018] with the U.S. Patent Trial and Appeal Board (PTAB) in regard to its denials of FTO’s petitions for Post Grant Review of Compass Pathways’ Patents No. 10,947,257 and 10,954,259 directed to compositions and oral dosage forms containing its “Polymorph A” of…

HAVN Life Announces Financing Commitment of C$9,000,000 through the issuance of Convertible Debentures and Warrants

Jul 25 • 5 min read

HAVN Life Sciences Inc. (CSE: HAVN | OTC: HAVLF | FSE: 5NP), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that Alpha Blue Ocean is supporting the Company’s growth with a CAD$‎‎9,000,000 ‎‎financing arrangement whereby the Company will issue up to $10.6 million principal amount of Convertible Debentures…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441